Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-07-09 8:06 pm Sale | 2025-07-07 | 13D | Passage Bio, Inc. PASG | ORBIMED ADVISORS LLC | 5,923,534 9.500% | -726,466 (-10.92%) | Filing History |
| 2025-06-18 8:23 pm Purchase | 2025-06-14 | 13D | Ikena Oncology, Inc. IKNA | ORBIMED ADVISORS LLC | 8,008,913 16.710% | 5,819,802 (+265.85%) | Filing History |
| 2025-06-17 5:30 pm Unchanged | 2025-06-16 | 13D | Enliven Therapeutics, Inc. ELVN | ORBIMED ADVISORS LLC | 7,918,163 13.400% | 0 (Unchanged) | Filing History |
| 2025-05-15 8:15 pm Unchanged | 2025-03-31 | 13G | NeuroPace, Inc. NPCE | ORBIMED ADVISORS LLC | 3,406,335 10.500% | 0 (Unchanged) | Filing History |
| 2025-05-15 8:13 pm Unchanged | 2025-03-31 | 13G | InspireMD, Inc. NSPR | ORBIMED ADVISORS LLC | 2,133,405 7.200% | 0 (Unchanged) | Filing History |
| 2025-05-15 8:09 pm Purchase | 2025-03-31 | 13G | C4 Therapeutics, Inc. CCCC | ORBIMED ADVISORS LLC | 4,655,600 6.600% | 4,655,600 (New Position) | Filing History |
| 2025-05-15 6:46 pm Purchase | 2025-03-31 | 13G | Whitehawk Therapeutics Inc WHWK | ORBIMED ADVISORS LLC | 4,166,000 8.900% | 4,166,000 (New Position) | Filing History |
| 2025-05-15 6:41 pm Sale | 2025-03-31 | 13G | Verastem, Inc. VSTM | ORBIMED ADVISORS LLC | 2,862,448 5.600% | -1,286,414 (-31.01%) | Filing History |
| 2025-05-14 8:49 pm Unchanged | 2025-05-12 | 13D | Corvus Pharmaceuticals, Inc. CRVS | ORBIMED ADVISORS LLC | 9,785,423 12.200% | 0 (Unchanged) | Filing History |
| 2025-05-12 7:13 pm Purchase | 2025-05-09 | 13D | Edgewise Therapeutics, Inc. EWTX | ORBIMED ADVISORS LLC | 15,252,867 14.500% | 496,771 (+3.37%) | Filing History |
| 2025-05-01 9:20 pm Purchase | 2025-04-29 | 13D | Corvus Pharmaceuticals, Inc. CRVS | ORBIMED ADVISORS LLC | 9,785,423 13.800% | 2,841,769 (+40.93%) | Filing History |
| 2025-04-25 7:48 pm Sale | 2025-04-22 | 13D | Passage Bio, Inc. PASG | ORBIMED ADVISORS LLC | 6,650,000 10.700% | -754,869 (-10.19%) | Filing History |
| 2025-04-14 7:09 pm Sale | 2025-04-10 | 13D | Xtant Medical Holdings, Inc. XTNT | ORBIMED ADVISORS LLC | 0 0.000% | -73,114,592 (Position Closed) | Filing History |
| 2025-04-11 7:21 pm Sale | 2024-04-09 | 13D | Compass Therapeutics, Inc. CMPX | ORBIMED ADVISORS LLC | 15,219,994 11.000% | -3,571,428 (-19.01%) | Filing History |
| 2025-03-12 7:57 pm Sale | 2025-03-10 | 13D | Disc Medicine, Inc. IRON | ORBIMED ADVISORS LLC | 1,556,369 4.500% | -229,202 (-12.84%) | Filing History |
| 2025-02-14 4:35 pm Purchase | 2024-12-31 | 13G | ADC Therapeutics S.A. ADCT | ORBIMED ADVISORS LLC | 3,437,813 3.600% | 3,437,813 (New Position) | Filing History |
| 2025-02-14 4:32 pm Purchase | 2024-12-31 | 13G | RAPT Therapeutics, Inc. RAPT | ORBIMED ADVISORS LLC | 13,135,260 9.900% | 13,135,260 (New Position) | Filing History |
| 2025-02-14 4:30 pm Purchase | 2024-12-31 | 13G | Corbus Pharmaceuticals Holdings, Inc. CRBP | ORBIMED ADVISORS LLC | 718,200 5.900% | 129,000 (+21.89%) | Filing History |
| 2025-02-14 4:22 pm Purchase | 2024-12-31 | 13G | Forte Biosciences, Inc. FBRX | ORBIMED ADVISORS LLC | 510,000 8.000% | 510,000 (New Position) | Filing History |
| 2025-02-13 4:47 pm Purchase | 2025-02-10 | 13D | Sionna Therapeutics, Inc. SION | ORBIMED ADVISORS LLC | 3,704,959 8.400% | 3,704,959 (New Position) | Filing History |